Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
REGENXBIO Inc.
RGNX
$7.40
Name : REGENXBIO Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $488,497,632.00
EPSttm : -3.78
finviz dynamic chart for RGNX
REGENXBIO Inc.
$7.40
2.21%
$0.16
RGNX — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

12.98

Margin Of Safety %

Put/Call OI Ratio

0.46

EPS Next Q Diff

-1.39

EPS Last/This Y

0.24

EPS This/Next Y

0.52

Price

7.39

Target Price

22.09

Analyst Recom

1.55

Performance Q

-29.39

Upside

-1,226.8%

Beta

1.12

Ticker: RGNX




19 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-08-28RGNX9.680.830.108244
2026-08-31RGNX9.50.810.278417
2026-09-02RGNX9.60.800.008608
2026-09-03RGNX9.190.782.888689
2026-09-04RGNX8.930.782.068754
2026-09-08RGNX8.740.762.978923
2026-09-09RGNX8.720.7630.798965
2026-09-10RGNX8.550.880.689619
2026-09-11RGNX8.520.861.069959
2026-09-14RGNX8.690.840.7010130
2026-09-15RGNX7.940.850.7810133
2026-09-16RGNX7.970.840.0610211
2026-09-17RGNX8.220.820.4810215
2026-09-18RGNX8.030.770.129909
2026-09-21RGNX7.880.480.046362
2026-09-22RGNX8.150.460.266612
2026-09-23RGNX7.490.430.656981
2026-09-24RGNX7.240.437.427003
2026-09-25RGNX7.390.463.607175
DateSymbolLatestP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-08-28RGNX9.58-5.7- -3.52
2026-08-31RGNX9.49-5.7- -3.52
2026-09-01RGNX9.32-5.7- -3.52
2026-09-02RGNX9.60-5.7- -3.52
2026-09-03RGNX9.15-5.7- -3.52
2026-09-04RGNX8.93-5.7- -3.52
2026-09-08RGNX8.74-5.7- -3.52
2026-09-10RGNX8.56-5.7- -3.52
2026-09-11RGNX8.53-5.7- -3.52
2026-09-14RGNX8.68-5.7- -3.52
2026-09-15RGNX7.94-5.7- -3.52
2026-09-16RGNX7.94-5.7- -3.52
2026-09-17RGNX8.22-5.7- -3.52
2026-09-18RGNX8.02-5.7- -3.52
2026-09-21RGNX7.88-5.7- -3.52
2026-09-22RGNX8.15-5.7- -3.52
2026-09-23RGNX7.49-5.7- -3.52
2026-09-24RGNX7.23-5.7- -3.52
2026-09-25RGNX7.39-5.7- -3.52
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-08-28RGNX0.44-0.5613.52
2026-08-31RGNX0.44-0.5613.41
2026-09-01RGNX0.49-0.5613.41
2026-09-02RGNX0.49-0.5613.41
2026-09-03RGNX0.47-0.5613.44
2026-09-04RGNX0.47-0.5613.44
2026-09-08RGNX0.47-0.4513.44
2026-09-09RGNX0.47-0.4513.44
2026-09-10RGNX0.47-0.4513.44
2026-09-11RGNX0.47-0.4512.29
2026-09-14RGNX0.58-0.4512.28
2026-09-15RGNX0.58-0.4512.28
2026-09-16RGNX0.58-0.4512.28
2026-09-17RGNX0.58-0.4512.28
2026-09-18RGNX0.58-0.4512.28
2026-09-21RGNX0.58-0.4512.28
2026-09-23RGNX0.58-0.4512.28
2026-09-24RGNX0.58-0.4512.28
2026-09-25RGNX0.58-0.4512.98
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS​

0.43

Avg. EPS Est. Current Quarter

-1.27

Avg. EPS Est. Next Quarter

-0.96

Insider Transactions

0.58

Institutional Transactions

-0.45

Beta

1.12

Average Sales Estimate Current Quarter

16

Average Sales Estimate Next Quarter

38

Fair Value

Quality Score

35

Growth Score

42

Sentiment Score

19

Actual DrawDown %

83.4

Max Drawdown 5-Year %

-87.8

Target Price

22.09

P/E

Forward P/E

PEG

P/S

2.8

P/B

5.59

P/Free Cash Flow

EPS

-3.79

Average EPS Est. Cur. Y​

-3.52

EPS Next Y. (Est.)

-3

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-112.58

Relative Volume

0.74

Return on Equity vs Sector %

-100

Return on Equity vs Industry %

-100

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

-0.73

EBIT Estimation

◆ RGNX Healthcare
$7.40
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
18/20
Pullback
19/25
Volume
9/15
Valuation
12/20
TP/AR
1/10
Options
6/10
RSI
34.7
Range 1M
5.7%
Sup Dist
4.2%
🚀
Momentum Growth
Ride accelerating trends
N/A
31 /100
WEAK
Momentum
6/25
Growth
18/30
Estimates
1/20
Inst/Vol
0/15
Options
6/10
EPS Yr
10.4%
EPS NY
13.6%
52W%
17.1%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +198.5% upside
Quality
6/30
Valuation
16/30
Growth
15/25
Stability
4/10
LT Trend
4/5
Upside
+198.5%
Quality
35
RGNX — P/E HistoricalBiotechnology
REGENXBIO Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 371
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
RGNX

Latest News

—
Caricamento notizie per RGNX…
stock quote shares RGNX – REGENXBIO Inc. Stock Price stock today
news today RGNX – REGENXBIO Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch RGNX – REGENXBIO Inc. yahoo finance google finance
stock history RGNX – REGENXBIO Inc. invest stock market
stock prices RGNX premarket after hours
ticker RGNX fair value insiders trading